Profile data is unavailable for this security.
About the company
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.
- Revenue in USD (TTM)0.00
- Net income in USD-13.73m
- Incorporated2014
- Employees37.00
- LocationNeuBase Therapeutics Inc350 Technology DrivePITTSBURGH 15219United StatesUSA
- Phone+1 (412) 763-3350
- Fax+1 (302) 655-5049
- Websitehttps://www.neubasetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRI Bio Inc | 0.00 | -13.04m | 1.31m | 4.00 | -- | 1.02 | -- | -- | -33.75 | -33.75 | 0.00 | 0.4011 | 0.00 | -- | -- | 0.00 | -366.83 | -192.93 | -1,002.46 | -353.99 | -- | -- | -- | -37,650.49 | -- | -6.00 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| InVitro International | 716.89k | 6.22k | 1.37m | 16.00 | 171.43 | 1.87 | -- | 1.90 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
| Lucy Scientific Discovery Inc | 16.73k | -9.76m | 1.45m | -- | -- | 17.81 | -- | 86.41 | -6.34 | -7.21 | 0.0103 | 0.046 | 0.0037 | -- | 0.7276 | -- | -215.45 | -- | -- | -- | 49.97 | -- | -58,360.55 | -- | -- | -5.10 | 0.4615 | -- | -- | -- | -53.49 | -- | -- | -- |
| Virax Biolabs Group Ltd | 0.00 | -1.71m | 1.45m | 5.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.8568 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 0.0223 | -112.29 | -- | -- | -100.00 | -- | -162.50 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 5.49m | -6.35m | 1.47m | 13.00 | -- | 0.1074 | -- | 0.2671 | -1.65 | -1.65 | 1.22 | 2.25 | 0.3411 | 2.87 | 24.14 | -- | -39.48 | -88.10 | -45.22 | -104.19 | 38.42 | -- | -115.75 | -1,066.11 | 6.58 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.95m | 1.47m | 10.00 | -- | 0.2341 | -- | -- | -9.18 | -9.18 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -108.25 | -- | -132.91 | -- | -- | -- | -- | -- | -- | -- | 0.0059 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| LadRx Corp | 0.00 | 331.63k | 1.49m | 2.00 | 5.12 | 13.84 | 4.32 | -- | 0.5857 | 0.5857 | 0.00 | 0.2168 | 0.00 | -- | -- | 0.00 | 17.58 | -58.97 | 480.72 | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Bioquest Corp | 0.00 | -507.41k | 1.49m | -- | -- | -- | -- | -- | -0.0485 | -0.0485 | 0.00 | -0.0467 | 0.00 | -- | -- | -- | -3,483.76 | -- | -- | -- | -- | -- | -- | -- | -- | -3.88 | -- | -- | -- | -- | 64.67 | -- | -- | -- |
| Neubase Therapeutics Inc | 0.00 | -13.73m | 1.52m | 37.00 | -- | 0.1653 | -- | -- | -7.78 | -7.78 | 0.00 | 2.45 | 0.00 | -- | -- | -- | -53.51 | -- | -64.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 1.54m | 0.00 | -- | 0.8665 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| Link Reservations Inc | 0.00 | -480.90k | 1.59m | 0.00 | -- | -- | -- | -- | -46.51 | -46.51 | 0.00 | -13.99 | 0.00 | -- | -- | -- | -246.84 | -- | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -22.69 | -- | -- | -- |
| Mallinckrodt PLC | 1.87bn | -1.67bn | 1.60m | 2.80k | -- | -- | -- | 0.0009 | -177.21 | -177.20 | 94.84 | 58.90 | 0.3829 | 1.53 | 4.77 | 666,392.90 | -34.26 | -12.49 | -39.27 | -15.85 | 20.70 | 35.68 | -89.47 | -44.38 | 1.55 | -0.4599 | 0.603 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -19.94m | 1.71m | 4.00 | -- | -- | -- | -- | -64.01 | -64.01 | 0.00 | -0.2389 | 0.00 | -- | -- | 0.00 | -160.06 | -42.39 | -280.99 | -56.41 | -- | -- | -- | -- | -- | -- | 1.14 | -- | -- | -- | 48.52 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Greenlight Capital, Inc.as of 31 Dec 2023 | 136.35k | 3.66% |
| UBS Securities LLCas of 31 Dec 2023 | 65.72k | 1.76% |
| Point72 Asset Management LPas of 31 Dec 2023 | 62.50k | 1.68% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 56.97k | 1.53% |
| Carnegie Mellon University (Investment Management)as of 31 Dec 2023 | 46.97k | 1.26% |
| Two Sigma Investments LPas of 31 Dec 2023 | 21.08k | 0.57% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 18.98k | 0.51% |
| Kestra Advisory Services LLCas of 31 Dec 2023 | 16.48k | 0.44% |
| Jacob Asset Management of New York LLCas of 30 Sep 2023 | 15.66k | 0.42% |
| Prelude Capital Management LLCas of 31 Dec 2023 | 15.55k | 0.42% |
